

Use of *Apretude* for Pre-Exposure Prophylaxis in People Who Inject Drugs

Summary

- Data on the use of *Apretude* (long-acting cabotegravir, CAB LA) for pre-exposure prophylaxis in people who inject drugs are currently unavailable.
- Participants were excluded from HPTN 083 and 084 if alcohol or substance use was noted that, in the opinion of the study investigator, would interfere with the conduct of the study (e.g., provided by self-report, or found upon medical history and examination or in available medical records)^{1,2}
- CAB LA is not approved for use as PrEP to prevent transmission of HIV-1 associated with injection drug use.
- Important Safety Information and Boxed Warning can be found in the <u>Prescribing Information</u> and can also be accessed from the <u>Our HIV Medicines</u> section of viivhealthcare.com/us.

To access additional scientific information related to ViiV Healthcare medicines, visit the ViiV US Medical Portal at <u>viivhcmedinfo.com</u>.



This information is scientific and non-promotional in nature and is not intended for further distribution.

This product or the described use of this product has not been approved by the FDA; therefore, no conclusions should be drawn about the safety or efficacy of this product. This information is not intended to offer recommendations for using this product in a manner inconsistent with its approved labeling. Please consult the applicable Prescribing Information. For ViiV Healthcare to monitor the safety of our products, we encourage healthcare professionals to report adverse events or suspected overdoses to the company at 877-844-8872.

Selection of references follows principles of evidence-based medicine and, therefore, references may not be all inclusive.



REFERENCES

- NCTo2720094 (HPTN 083). Available at: https://clinicaltrials.gov/ct2/show/NCTo2720094?term=cabotegravir+prep&rank=1. Accessed October 3, 2019.
- 2. NCTo3164564 (HPTN 084). Available at: https://clinicaltrials.gov/ct2/show/NCTo3164564?term=cabotegravir+prep&rank=3. Accessed October 3, 2019.